Each tablet contains Favipiravir INN 200 mg.
Favipiravir is an anti-influenza drug. The antiviral targets RNA dependent RNA polymerase (RdRp) enzymes, which are necessary for transcription and replication of viral genomes.
Favipiravir is approved to treat cases of influenza. It has been investigated to treat novel viruses including Ebola.
Influenza: The usual dosage of Favipiravir for adults is 1600 mg twice daily in Day 1 followed by 600 mg orally two times daily for 4 days. The total administration period will be 5 days.
Raised serum uric acid level, liver & kidney injury, flatulence, decreased count of WBC, neutrophil & platelet, hallucination, delusion, shock, anaphylaxis and jaundice.
It is only considered in outbreak of re-emerging influenza viral infections and it is not effective in bacterial infections. Pediatric use: It is not indicated for administration to pediatrics.
Geriatric use: Favipiravir should be administered with care in elderly patients by monitoring their general & vital conditions.
No clinical data was available for pregnant women being treated with Favipiravir. It is not known whether it is excreted in human milk. Mothers should be instructed not to breast feed if they are taking Favipiravir
Toxicity for over dosing information regarding Favipiravir in human body is not readily available.
Do not store above 30°C. Keep away from light and out of reach of children.
Each box contains 2 blister strips of 10 tablets